5 Jan 2017 07:00
Realm Therapeutics plc
("Realm Therapeutics", "Realm" or the "Company")
Realm Therapeutics to present at the 2017 Dermatology Summit and Biotech Showcase
Company on track to initiate two Phase II clinical trials in 2017
5 January 2017 - Realm Therapeutics plc (AIM: RLM), an emerging specialty biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Alex Martin, CEO, will be presenting at both the 4th Annual Dermatology Summit on January 8 (2:30 pm PT at the Palace Hotel), and the Biotech Showcase on January 10 (4:00 pm PT at the Hilton Union Square) in San Francisco coinciding with the 2017 J.P. Morgan Healthcare Conference.
Mr. Martin will review the Company's two drug development programs - PR022 for Atopic Dermatitis and PR013 for Allergic Conjunctivitis, summary details of which were announced in the Company's Development Programmes update on 16 November 2016. Following successful pre-Investigational New Drug (IND) meetings with the U.S. Food and Drug Administration in 2016, Realm plans to submit two INDs in 2017 (Q1 for Atopic Dermatitis; Q3 for Allergic Conjunctivitis) and begin a Phase II study on each shortly thereafter.
Alex Martin, Chief Executive Officer of Realm Therapeutics, said:
"2016 was an important transitional year: we divested our non-core business to fund our drug development programs, changed our name to Realm Therapeutics, and successfully emerged as a clinical stage specialty pharmaceutical company. 2017 will be an exciting year as we enter Phase II with both our lead programs and we look forward to further promising developments."
Enquiries:
Realm Therapeutics plc | +44 (0) 20 3727 1000 |
Alex Martin, Chief Executive Officer | |
Marella Thorell, Chief Financial Officer and Chief Operating Officer | |
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway / Mo Noonan | |
N+1 Singer (Nominated Adviser and Broker) | +44 (0) 20 7496 3000 |
Aubrey Powell / Lauren Kettle |
About Realm Therapeutics
Realm Therapeutics is an emerging specialty biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas including Dermatology and Ophthalmology.
Forward looking statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.